Next Article in Journal
Lipid Saturation and the Rheology of Human Tear Lipids
Next Article in Special Issue
Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia
Previous Article in Journal
Human DNA Virus Exploitation of the MAPK-ERK Cascade
Previous Article in Special Issue
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Open AccessReview

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

1
Institut National de la Santé et de la Recherche Médicale, U1035 Bordeaux, France
2
Université de Bordeaux, 33076 Bordeaux, France
3
CHU Bordeaux, Service d’Hématologie Clinique et Thérapie Cellulaire, F-33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(14), 3429; https://doi.org/10.3390/ijms20143429
Received: 21 June 2019 / Revised: 8 July 2019 / Accepted: 10 July 2019 / Published: 12 July 2019
(This article belongs to the Special Issue Drug Resistance in Hematologic Malignancies)
  |  
PDF [686 KB, uploaded 12 July 2019]
  |     |  

Abstract

Acute myeloid leukemia (AML) is a myeloid malignancy carrying a heterogeneous molecular panel of mutations participating in the blockade of differentiation and the increased proliferation of myeloid hematopoietic stem and progenitor cells. The historical “3 + 7” treatment (cytarabine and daunorubicin) is currently challenged by new therapeutic strategies, including drugs depending on the molecular landscape of AML. This panel of mutations makes it possible to combine some of these new treatments with conventional chemotherapy. For example, the FLT3 receptor is overexpressed or mutated in 80% or 30% of AML, respectively. Such anomalies have led to the development of targeted therapies using tyrosine kinase inhibitors (TKIs). In this review, we document the history of TKI targeting, FLT3 and several other tyrosine kinases involved in dysregulated signaling pathways. View Full-Text
Keywords: acute myeloid leukemia; tyrosine kinase; inhibitors; targeted therapy acute myeloid leukemia; tyrosine kinase; inhibitors; targeted therapy
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fernandez, S.; Desplat, V.; Villacreces, A.; Guitart, A.V.; Milpied, N.; Pigneux, A.; Vigon, I.; Pasquet, J.-M.; Dumas, P.-Y. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? Int. J. Mol. Sci. 2019, 20, 3429.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top